JEFFREY A. BLUESTONE, PH.D. - Corporate Board Profile

GILEAD SCIENCES, INC.

Filing Date	Source Excerpt
2021-03-30	Jeffrey A. Bluestone, Ph.D. New INDEPENDENT AGE: 67 DIRECTOR SINCE: 2020 COMMITTEES: Science Dr. Bluestone joined our Board in December 2020. ... Our Board unanimously recommends a vote FOR each named director nominee: Jeffrey A. Bluestone ... 2020 Director Compensation ... Jeffrey A. Bluestone $53,356 cash, $63,678 options, $63,754 RSUs, total $180,788.
2022-03-24	Jeffrey A. Bluestone, Ph.D. Independent Dr. Bluestone joined our Board in December 2020. Dr. Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics, Inc., a role he has held since 2019. From 2015 to 2019, he led the Parker Institute for Cancer Immunotherapy as President and Chief Executive Officer. Dr. Bluestone is the A.W. and Mary Margaret Clausen Distinguished Professor in the Diabetes Center at University of California San Francisco, where he has been a member of the faculty and served in various other roles for over 20 years, including the Director of the Diabetes Center from 2000 to 2019. He is an international leader in the field of immunotherapy and has published more than 500 papers over nearly four decades focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development of multiple immunotherapies, including the first medicine approved by the U.S. Food and Drug Administration (FDA) targeting T-cell co-stimulation to treat autoimmunity and the first FDA-approved checkpoint inhibitor for the treatment of metastatic melanoma and other cancers. Dr. Bluestone was the founding director of the Immune Tolerance Network, the largest National Institutes of Health-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity and asthma/allergy. He served as a member of the Blue Ribbon Panel, appointed by then Vice President Joe Biden, to guide the National Cancer Moonshot Initiative. Dr. Bluestone is a member of the National Academy of Medicine and American Academy of Arts and Sciences, was a recipient of the prestigious Guggenheim Fellowship, and previously served as the Ludwig Professor and Director of the Ben May Institute at the University of Chicago. He currently serves on the board of directors of Provention Bio, Inc. Relevant Skills And Experience: Internationally-recognized leader in the field of immunotherapy and related fields, with a distinguished scientific and academic career spanning nearly four decades. Strong leadership experience in the healthcare industry. Other Public Company Board Service: ● Provention Bio, Inc. 2021 Director Compensation The table below summarizes the compensation paid by us to our non-employee Board members for the 2021 fiscal year: Jeffrey A. Bluestone $47,890 Fees Earned or Paid in Cash $149,941 Stock Awards $149,991 Option Awards $347,822 Total
2023-03-23	Jeffrey A. Bluestone, Ph.D. Independent Dr. Bluestone joined our Board in December 2020. Dr. Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics, Inc., a role he has held since 2019. From 2015 to 2019, he led the Parker Institute for Cancer Immunotherapy as President and Chief Executive Officer. Dr. Bluestone is the A.W. and Mary Margaret Clausen Distinguished Professor Emeritus in the Diabetes Center at University of California San Francisco, where he has been a member of the faculty and served in various other roles for over 20 years, including the Director of the Diabetes Center from 2000 to 2019. He is an international leader in the field of immunotherapy and has published more than 500 papers over nearly four decades focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development of multiple immunotherapies, including the first medicine approved by the U.S. Food and Drug Administration (FDA) to delay/prevent autoimmune Type 1 diabetes and the first FDA-approved checkpoint inhibitor for the treatment of metastatic melanoma and other cancers. Dr. Bluestone was the founding director of the Immune Tolerance Network, the largest National Institutes of Health-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity and asthma/allergy. He served as a member of the Blue Ribbon Panel, appointed by then Vice President Joe Biden, as a member of the National Cancer Moonshot Task Force. Dr. Bluestone is a member of the National Academy of Medicine and American Academy of Arts and Sciences, was a recipient of the prestigious Guggenheim Fellowship, and previously served as the Ludwig Professor and Director of the Ben May Institute at the University of Chicago. He previously served on the board of directors of Provention Bio, Inc. from 2013 to 2022. Relevant Skills and Experience: Internationally-recognized leader in the field of immunotherapy and related fields, with a distinguished scientific and academic career spanning nearly four decades. Strong leadership experience in the healthcare industry. Other Public Company Board Service: None 2022 Director Compensation Jeffrey A. Bluestone $95,000 cash + $149,939 stock awards + $149,993 option awards = $394,932 total annual compensation.
2024-03-28	Jeffrey A. Bluestone, Ph.D. Age 70 Director Since 2020 Committees: Science Other Public Company Board Service: None
2025-03-27	Jeffrey A. Bluestone, Ph.D. Independent Age: 71 Director since: 2020 Committees: ► Science 2024 Director Compensation Jeffrey A. Bluestone, Ph.D. Fees Earned or Paid in Cash 95,000 Stock Awards 149,965 Option Awards 149,995 All Other Compensation 15,000 Total 409,960